Guggenheim Names Top Stock Pick in Biotech Sector
Investing.com reports Guggenheim named Surrozen Inc. (SRZN) its top biotech stock pick, reiterating a Buy rating. The focus is the Phase IIb/III BRUNELLO readout, with primary completion expected in September and full data potentially in October. Guggenheim cites potential upside of 2 to 3 times current levels and highlights SRZN-8141/8143 and upcoming DUET timing.
How this was made
The 30-second read
Why it matters
The main tradable element is the calendar of upcoming clinical and regulatory milestones that can affect expectations and positioning ahead of trial readouts.
Market read
This is a catalyst-driven biotech positioning story centered on ophthalmology trial timing rather than a new clinical result or regulatory decision.
What to watch
Key risk is whether BRUNELLO demonstrates non-inferiority or superiority on best corrected visual acuity and/or central subfield thickness; the article also notes no MoA has yet shown non-inferiority to anti-VEGF in pivotal studies.
Background
Guggenheim held a non-deal roadshow with Surrozen management and reiterated a Buy rating, emphasizing its Wnt biology platform for ophthalmology unmet needs.
Ticker impact
Guggenheim names Surrozen (SRZN) its top biotech pick, citing an upcoming Phase IIb/III BRUNELLO readout and IND timing for SRZN-8141.
Bias toward upside into the September readout if trial signals are strong; otherwise expect volatility around the catalyst window.
The article provides specific, time-bound clinical and regulatory-planning milestones plus a reiterated Buy stance, which can drive positioning ahead of trial data.
Market effects
If BRUNELLO supports Wnt biology add-on potential versus anti-VEGF benchmarks, it could lift sentiment for ophthalmology-focused biotech platforms.
No specific regional market linkage beyond US biotech sentiment and AAO-related attention.
Ophthalmology trial readouts can influence global peers working on diabetic macular edema and wet AMD, but the article is US-focused.
Counterpoint
The piece is an analyst top-pick reiteration and may not reflect new trial results; the “2 to 3 times” upside is not a disclosed datapoint.
Key entities
- companySurrozen Inc.
SRZN, Guggenheim’s top biotech pick, with Phase IIb/III BRUNELLO readout expected after September completion and SRZN-8141 IND planned by end of Q3 2026.
- clinical_trialBRUNELLO study
Phase IIb/III trial whose primary completion is expected in September, with full data potentially presented at the American Academy of Ophthalmology in October.
- drug_candidateSRZN-8141
Wnt agonist candidate; IND submission now anticipated by end of Q3 2026 per the article.
- drug_candidateSRZN-8143
More potent Wnt agonist described as having additional anti-VEGF and anti-IL-6 activity.
- clinical_trialDUET study
Phase Ib/IIa study expected to begin by year-end 2026, with data expected in second half of 2027.
